Granular corneal dystrophy is an eye condition affecting about one in a thousand people with no current cure. Early diagnosis can help with prevention and warn patients when not to have LASIK and other corneal surgeries, resulting in protein formations in the eye and vision loss. Avellino Lab's proprietary and patented DNA sequencing test detects an individual's risk for this genetic condition. Avellino is also working on tests for other rare ophthalmic diseases which can lead to vision loss.
Avellino Labs provides eye care professionals a rapid and inexpensive screening test to further ensure patients cleared for refractive surgery are good candidates. We test for multiple single point gene mutations associated with the most common types of corneal dystrophy, a condition that may not effect vision until triggered by refractive surgery.
|HQ||Menlo Park, US||Map|
|Employees (est.) (Feb 2019)||26||(+9%)|
Avellino Labs has 205 Twitter Followers. The number of followers has decreased 1.5% quarter over quarter
When was Avellino Labs founded?
Avellino Labs was founded in 2012.
How many employees does Avellino Labs have?
Avellino Labs has 26 employees.
Who are Avellino Labs competitors?
Competitors of Avellino Labs include Gemini Therapeutics, Avrobio and Mission Bio.
Where is Avellino Labs headquarters?
Avellino Labs headquarters is located at 1505 Adams Dr, Menlo Park.
Where are Avellino Labs offices?
Avellino Labs has an office in Menlo Park.
How many offices does Avellino Labs have?
Avellino Labs has 1 office.